1. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States;Bartsch;Clin Microbiol Infect,2017
2. Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, second update –26 September 2019,2019
3. European Medicines Agency (EMA). Summary of opinion – ZaviceftaTM. EMA/CHMP/266959/2016. 2016. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zavicefta_en.pdf.
4. U.S. Food and Drug Administration (FDA). Approval letter - ceftazidime-avibactam for complicated urinary tract infections including pyelonephritis and complicated intra-abdominal infections. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000Approv.pdf.
5. European Medicines Agency (EMA). VabomereTM (meropenem/vaborbactam): an overview of Vabomere and why it is authorised in the EU. 2018. https://www.ema.europa.eu/en/documents/overview/vabomere-epar-medicine-overview_en.pdf.